Gamida Cell Ltd. (GMDA)
| Market Cap | 464.54M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -34.35M |
| Shares Out | 24.93M |
| EPS (ttm) | -1.81 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 19 |
| Last Price | $9.84 |
| Previous Close | $9.39 |
| Change ($) | 0.45 |
| Change (%) | 4.79% |
| Day's Open | 9.92 |
| Day's Range | 9.75 - 10.48 |
| Day's Volume | 1,397,603 |
| 52-Week Range | 2.79 - 11.00 |
BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to cures for blood cancers and serious hematologic diseases, today announced that the full ...
BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to cures for blood cancers and serious blood diseases, announced today that company managem...
BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to cures for blood cancers and serious hematologic diseases, today announced that its previ...
BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to cures for blood cancers and serious hematologic diseases, today announced that it has be...
BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to cures for blood cancers and serious hematologic diseases, today announced the pricing of...
BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to cures for blood cancers and serious hematologic diseases, today announced the launch of ...
BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to cures for blood cancers and serious hematologic diseases, today announced that the compa...
Early data for this company's natural killer cells is drawing lots of attention.
BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to cures for blood cancers and serious hematologic diseases, today will be providing an upd...
Gamida Cell (NASDAQ: GMDA) shares are trading higher on Monday following the company's Saturday GDA-201 presentation at the American Society of Hematology Annual Meeting. Gamida Cell is a biop...
BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to cures for blood cancers and serious hematologic diseases, today announced in an oral pre...
BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to cures for blood cancers and serious blood diseases, announced today that it will host a ...
BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to cures for blood cancers and serious blood diseases, today announced that Julian Adams, C...
Gamida Cell Ltd (GMDA) CEO Julian Adams on Q3 2020 Results - Earnings Call Transcript
BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to finding cures for blood cancers and serious blood diseases, today reported financial res...
BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), a leading cellular and immune therapeutics company, today announced that updated data from the ongoing Phase 1 clinical study of GDA-2...
BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to cures for blood cancers and serious blood diseases, today announced that Julian Adams, P...
BOSTON--(BUSINESS WIRE)---- $GMDA #BMT--Gamida Cell announced that it will report its third quarter 2020 financial results and provide a company update on November 10, 2020.
Gamida Cell recently executed a secondary at $4.50 a share on the back of positive Phase 3 clinical data for its lead asset. The cell therapy biotech now trades at half its 2018 post IPO price...
BOSTON & MINNEAPOLIS--(BUSINESS WIRE)---- $GMDA #BMT--Gamida Cell and Be The Match BioTherapies® today announced an expansion of their strategic collaboration for investigational omidubicel.
Gamida Cell (GMDA) saw a big move last session, as its shares jumped more than 8% on the day, amid huge volumes.
BOSTON--(BUSINESS WIRE)---- $GMDA #BMT--Gamida Cell will present at the annual Cell & Gene Meeting on the Mesa to be held virtually October 12 - 16, 2020.
BOSTON--(BUSINESS WIRE)---- $GMDA #BMT--Gamida Cell announced that its Phase 3 clinical study of omidubicel in bone marrow transplant met all three secondary endpoints.
BOSTON--(BUSINESS WIRE)---- $GMDA #BMT--Gamida Cell today announced data from an observational study being presented at the virtual Cord Blood Connect Meeting.
BOSTON--(BUSINESS WIRE)---- $GMDA--Gamida Cell will participate in three upcoming virtual investor conferences in September.
BOSTON--(BUSINESS WIRE)---- $GMDA #BMT--Gamida Cell will host a two-part virtual miniseries in September focused on key topics related to its investigational cell therapy omidubicel.
BOSTON--(BUSINESS WIRE)---- $GMDA--Gamida Cell will webcast its Annual Meeting of Stockholders on Thursday, September 10, 2020, at 10:00 a.m. ET.
Gamida Cell Ltd. (GMDA) CEO Julian Adams on Q2 2020 Results - Earnings Call Transcript
Shares of Gamida Cell (NASDAQ:GMDA) moved higher by 1.6% in pre-market trading after the company reported Q2 results.
Gamida Cell (GMDA) will provide updates on its pipeline candidates when it releases second-quarter 2020 results.
Is (GMDA) Outperforming Other Medical Stocks This Year?
Gamida Cell (GMDA) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Top Ranked Momentum Stocks to Buy for May 28th
Gamida Cell (GMDA) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Top Ranked Momentum Stocks to Buy for May 22nd
Gamida Cell Ltd. (GMDA) CEO Julian Adams on Q1 2020 Results - Earnings Call Transcript
Gamida Cell Ltd. (GMDA) CEO Julian Adams on Q4 2019 Results - Earnings Call Transcript
Gamida Cell Ltd. (GMDA) CEO Julian Adams on Q3 2019 Results - Earnings Call Transcript
Gamida Cell has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.
Gamida Cell Ltd. (GMDA) CEO Julian Adams on Q1 2019 Results - Earnings Call Transcript
About GMDA
Gamida Cell, a clinical-stage biopharmaceutical company, develops cell therapies to cure blood cancers and serious blood diseases. The company's lead product candidate is omidubicel, a nicotinamide expanded hematopoietic stem cells and differentiated immune cells, including T cells that is in Phase 3 studies in patients with high-risk hematologic malignancies, as well as in Phase 1/2 clinical trial in patients with severe aplastic anemia. It is also developing GDA-201, a natural killer cell-based cancer immunotherapy, which is in Phase 1/2 stud... [Read more...]
| Industry Biotechnology | IPO Date Oct 26, 2018 |
| CEO Dr. Julian Adams Ph.D. | Employees 79 |
| Stock Exchange NASDAQ | Ticker Symbol GMDA |
Analyst Forecasts
According to 7 analysts, the average rating for Gamida Cell stock is "Buy." The 12-month stock price forecast is 15.17, which is an increase of 54.17% from the latest price.